At any given time, we are working on several research projects across a range of disciplines and therapeutic areas. This work can span months to years. Our projects are heavily vetted and only those that meet our scientific and business criteria are formed into a company. This timeline is a snapshot of select major events along our journey to building companies and commercializing innovations.
InCube Labs is founded
Percusurge is founded
Reflow is acquired by Fox Hollow
Percusurge is acquired by Medtronic
Safeview is founded
Spinal Modulation is founded
Safeview is acquired by L3
InCube San Antonio is founded
Neurolink and Corhythm are founded
Rani Therapeutics is founded
Nfocus is acquired by Covidien
Zonare is acquired by Mindray
Theracle and iBridge are founded
Sacramed is founded
We deeply care about improving the quality of life of patients suffering from a number of debilitating conditions. We think through the problems we are trying to solve, always guided by what is best for the patients.
Our goal is to develop innovations that will be safe and highly effective, and ultimately will improve the lives of millions of patients.
A multi-disciplinary process is at the center of our work and allows us to address the most complex unsolved or poorly treated clinical needs. Our multi-disciplinary experience allows us to be agnostic to technology, and to focus on innovative solutions and on understanding how the problem wants to be solved.
Analytical biochemistry is a core area of expertise in drug discovery and development. We have a group of highly seasoned biochemists and molecular biologists who routinely run complex bioanalytical assays and are constantly looking at ways to improve the selectively and specificity of our analytical tools. Bioanalytical tools are critically important as they help generate the key end points for our biological studies.
As our companies mature and move towards the clinic, clinical and regulatory strategies and plans become a fundamental part of our work. We have access to world-class regulatory experts who have deep experience in devices, drugs and drug-device combinations. These experts help us devise and execute upon our regulatory strategy for each portfolio company, and work with us at each important stage on the path to commercialization.
Each of our locations has a team of engineers who are working on innovations across a variety of therapeutic diseases. In addition to creating unique medical devices, our engineers are focused on digital medicine solutions that enable connectivity and remote patient monitoring.
We have access to a team of world-class industrial designers who provide the insight and experience needed to create patient-friendly products. As part of our work, we will test prototypes with patients and physicians to make sure our designs meet requirements, but also provide the best user experience.
Our capabilities range from prototyping to full scale production. Our machine shop plays a key role as we develop prototypes to move our product concepts to reality. As a company evolves, we work on manufacturing optimization, scale up and automation. Our portfolio companies also have direct access to our manufacturing partner, Modulus, which has deep expertise in manufacturing Class II and Class III medical devices.
We have deep expertise in a range of biomaterials. We can optimize the properties of these materials for drug delivery, tissue engineering, active implants and sensors.
Our experienced team of mechanical engineers are at the heart of many of our most innovative companies and products. They are constantly developing ideas and refining product concepts, as well as designing and testing prototypes to create reliable, safe and efficacious products.
Every drug development program requires deep expertise in pharmacology and physiology. We have world-class pharmacologists who have successfully developed drugs and brought them to the market. In addition, our experienced physiologists have created disease paradigms and pre-clinical models that allow us to test our ideas before we go to the clinic.
More than half of portfolios in pharma companies consist of biologics, which are very difficult to create, isolate, purify and manufacture and test in disease models. Biologics have to be formulated in a very specific manner requiring a deep knowledge of protein biochemistry and the use of polymers to stabilize these biological entities and regulate their release. Our team has worked extensively with biologics and has a wealth of experience in protein and polymer chemistry.